There is a need for randomised controlled trials evaluating the effect of adding ARBs to patients taking ACE inhibitor therapy and beta-adrenergic antagonists for the treatment of heart failure in order to see whether ARBs offer any additional benefit to current standard therapy for heart failure. This evidence concerns the gene ACE and heart failure.